Ishihara, Mikiya http://orcid.org/0000-0002-7581-2615
Tono, Yasutaka http://orcid.org/0000-0002-9714-0629
Miyahara, Yoshihiro
Muraoka, Daisuke
Harada, Naozumi
Kageyama, Shinichi
Sasaki, Takeshi http://orcid.org/0000-0002-2458-5686
Hori, Yasuhide http://orcid.org/0000-0002-0053-995X
Soga, Norihito
Uchida, Katsunori
Shiraishi, Taizo
Sato, Eiichi
Kanda, Hideki
Mizuno, Toshiro
Webster, Gill A.
Ikeda, Hiroaki
Katayama, Naoyuki
Sugimura, Yoshiki
Shiku, Hiroshi
Funding for this research was provided by:
Cancer Research Institute
Article History
Received: 22 March 2019
Accepted: 4 January 2020
First Online: 24 January 2020
Compliance with ethical standards
:
: CHP-NY-ESO-1 was supplied by ImmunoFrontier Inc. (Osaka, Japan). N. Harada is a former employee of ImmunoFrontier Inc. H. Shiku is a stockholder of ImmunoFrontier Inc. MIS416 was supplied by Innate Immunotherapeutics Ltd. (Victoria, Australia). G.A. Webster is an employee of Innate Immunotherapeutics Ltd. The other authors declare that they have no conflicts of interest.
: All procedures performed in our studies involving human participants were conducted in accordance with Japanese Ethical Guidelines for Clinical Research, Japanese Guidelines for Medical and Health Research Involving Human Subjects, and the Helsinki declaration. The Institutional Review Board reviewed and approved the protocol and the informed consent documents and their amendments before use (Mie University approval numbers 817, 2201, 2203 and 2366). All animal experiments were conducted in accordance with the Fundamental Guidelines for Proper Conduct of Animal Experiment and Related Activities in Academic Research Institutions and approved by Mie University (Approval Number 24-14).
: Female BALB/c mice aged 6–10 weeks were purchased from Japan SLC, Inc. (Shizuoka, Japan).
: This study was presented in part at the 2016 Annual Meeting of the American Urological Association (AUA), May 8, 2016, San Diego, California, USA, Abstract 16-3843 [CitationRef removed] and at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1–5, 2018, Chicago, Illinois, USA, Abstract e15176 [CitationRef removed].
: The CT26 cell line (CRL-2638) was purchased from the American Type Culture Collection (Virginia, USA) and stably transfected with human NY-ESO-1 cDNA as described previously [CitationRef removed, CitationRef removed].
: Written informed consent to participate in the study and for the use of clinical data for research and publication was obtained from all patients included in the studies (Mie University Approval Numbers 2201, 2203 and 2366). Blood from healthy volunteers was obtained by laboratory members with the approval of Mie University (Approval Number 817). All healthy donors provided written informed consent to the use of their specimens for research and publication.
: To protect patient information in the clinical trial database, the datasets generated and/or analyzed in the present study are not publicly available, but they are available from the corresponding author on request.